Evidence map›Paper›PMID 27022223›Full record

ArticleWorld journal of gastroenterology2016

Two strategies for prevention of cytomegalovirus infections after liver transplantation.

Philipp Simon, Max Sasse, Sven Laudi, David Petroff, Michael Bartels, Udo X Kaisers, Sven Bercker

Open access · hybridAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 15 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Cytomegalovirus infection after liver transplantation.World journal of transplantation · 2020
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Philipp SimonPhilipp Simon, Max Sasse, Sven Laudi, Udo X Kaisers, Sven Bercker, Department of Anesthesia and Intensive Care Medicine, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.
Max SassePhilipp Simon, Max Sasse, Sven Laudi, Udo X Kaisers, Sven Bercker, Department of Anesthesia and Intensive Care Medicine, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.
Sven LaudiPhilipp Simon, Max Sasse, Sven Laudi, Udo X Kaisers, Sven Bercker, Department of Anesthesia and Intensive Care Medicine, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.
David PetroffPhilipp Simon, Max Sasse, Sven Laudi, Udo X Kaisers, Sven Bercker, Department of Anesthesia and Intensive Care Medicine, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.
Michael BartelsPhilipp Simon, Max Sasse, Sven Laudi, Udo X Kaisers, Sven Bercker, Department of Anesthesia and Intensive Care Medicine, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.
Udo X KaisersPhilipp Simon, Max Sasse, Sven Laudi, Udo X Kaisers, Sven Bercker, Department of Anesthesia and Intensive Care Medicine, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.
Sven BerckerPhilipp Simon, Max Sasse, Sven Laudi, Udo X Kaisers, Sven Bercker, Department of Anesthesia and Intensive Care Medicine, Medical Faculty, University of Leipzig, 04103 Leipzig, Germany.
Leipzig University · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimTo analyze differences in patients' clinical course, we compared two regimes of either preemptive therapy or prophylaxis after liver transplantation.

methodsThis retrospective study was reviewed and approved by the institutional review board of the University of Leipzig. Cytomegalovirus (CMV) prophylaxis with valganciclovir hydrochloride for liver transplant recipients was replaced by a preemptive strategy in October 2009. We retrospectively compared liver transplant recipients 2 years before and after October 2009. During the first period, all patients received valganciclovir daily. During the second period all patients included in the analysis were treated following a preemptive strategy. Outcomes included one year survival and therapeutic intervention due to CMV viremia or infection.

resultsBetween 2007 and 2010 n = 226 patients underwent liver transplantation in our center. n = 55 patients were D(+)/R(-) high risk recipients and were excluded from further analysis. A further 43 patients had to be excluded since CMV prophylaxis/preemptive strategy was not followed although there was no clinical reason for the deviation. Of the remaining 128 patients whose data were analyzed, 60 received prophylaxis and 68 were treated following a preemptive strategy. The difference in overall mortality was not significant, nor was it significant for one-year mortality where it was 10% (95%CI: 8%-28%, P = 0.31) higher for the preemptive group. No significant differences in blood count abnormalities or the incidence of sepsis and infections were observed other than CMV. In total, 19 patients (14.7%) received ganciclovir due to CMV viremia and/or infections. Patients who were treated according to the preemptive algorithm had a significantly higher rate risk of therapeutic intervention with ganciclovir [n = 16 (23.5%) vs n = 3 (4.9%), P = 0.003)].

conclusionThese data suggest that CMV prophylaxis is superior to a preemptive strategy in patients undergoing liver transplantation.

Indexed as

AdultAntiviral AgentsCytomegalovirusCytomegalovirus InfectionsDrug Administration ScheduleFemaleGanciclovirGermanyHumansLiver TransplantationMaleMiddle AgedRetrospective StudiesTime FactorsTreatment OutcomeValganciclovirAntiviral AgentsGanciclovirValganciclovirCytomegalovirusLiverPreemptiveProphylaxisTherapyTransplantationValganciclovir

Identifiers

PMID27022223
PMCPMC4806199
OpenAlexW2341253316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.